Pipeline Overview

Committed to developing transformative therapies for cardiac conditions.

Pipeline of Product Candidates

Orally Inhaled Flecainide for PAF

Atrial fibrillation (AF) is the most commonly encountered, sustained cardiac arrhythmia in clinical practice. The risk of developing AF increases with age and tends to be higher in males than in females. The disease presents with a wide spectrum of symptoms and severity and is progressive. Its current global prevalence is around 34 million patients, which is expected to increase as the general population ages. Paroxysmal AF accounts for approximately 39% of all diagnosed prevalent cases of AF.

Additional Cardiology Programs

InCarda is actively developing therapies for significant unmet needs in cardiovascular medicine and related conditions. Our intellectual property and development expertise are being applied to several additional therapies and diseases with the common goal of reaching clinical development and, ultimately, benefiting patients.

For more information about InCarda: